STOCK TITAN

BioVaxys Technology Corp - BVAXF STOCK NEWS

Welcome to our dedicated news page for BioVaxys Technology (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on BioVaxys Technology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioVaxys Technology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioVaxys Technology's position in the market.

Rhea-AI Summary
BioVaxys Technology Corp. completed the settlement of CAD$215,000 in debt through the issuance of 7,166,666 common shares at a deemed price of $0.03 per common share. The debt did not include accrued salaries to officers or directors, nor payments for Investor Relations Activities. Certain related parties, including BioVaxys CEO James Passin and COO and President Kenneth Kovan, participated in the debt settlement. The securities issued are subject to a four-month hold period from the date of issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
none
-
Rhea-AI Summary
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) has announced the execution of a non-binding Letter of Intent to acquire a core platform technology and entire immunotherapeutics intellectual property portfolio in oncology and other immunological fields. The company has been granted exclusivity while working on the drafting of a definitive agreement with an unnamed biotechnology company's former secured creditor. Investors are advised to use caution in trading the company's shares while discussions are underway, as there is no certainty of reaching a definitive acquisition agreement or completing any transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.53%
Tags
-
Rhea-AI Summary
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) announced the termination of the US Distribution Agreement for Papilocare and Immunocaps with Procare Health, while the EU clinical development partnership for their ovarian cancer vaccine BVX-0918 remains unchanged. This move allows BioVaxys to refocus on immunotherapeutics, strengthening their balance sheet and advancing initiatives related to immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.53%
Tags
none
Rhea-AI Summary
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) is in non-binding discussions to acquire an immunotherapeutics intellectual property portfolio in oncology and other immunological fields. No formal agreement is in place, and caution is advised for trading shares. There is no certainty of reaching an agreement or completing any transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.8%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.07%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.97%
Tags
none
BioVaxys Technology Corp

OTC:BVAXF

BVAXF Rankings

BVAXF Stock Data

8.49M
125.30M
6.61%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Etobicoke